Page 550 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

508 MEDICAMENTSINDUISANTOUSTABILISANTDES COUPURESDE L'ADN

DUGUÉ B. et MEUNIER B., How can iron salts mediate the degradation of nucleos(t)ides
by ellipticinium acetate via free radicals ?, Biochem. Biophys. Commun., 1985, 133
(1), 15-22
DUGUÉ B. et al, Covalent binding of ellipticinium acetate (NSC 264 137) to nucleic acids
of L 1210 cells in culture, Cancer Res., 1986, 46 (8), 3828-33.
PRATVIEL G. et al, Ribose as the preferential target for the oxidized form of elliptinium
acetate in ribonucleos(t)ides. Biological activities of the resulting adducts, J. Med.
Chem., 1986, 29 (8), 1350-55.
MONNOT M. et al, Probing intercalation and conformational effects of the anticancer
drug 2-methyl-9-ellipticinium acetate in DNA-fragments with circular dichroism. Eur.,
J. Biochem., 1992, 31 (31), 1035-9.
BERNARD S. et al, Metabolism of the antitumor drug N(2)-methyl-9-hydroxyelliptici-
nium : identification by surface-enhanced Raman spectroscopy of adducts formed
with amino acids and nucleic acids, Biospectroscopy, 1996, 2 (6), 377-89.
OHASHI M., OKI T., Ellipticine and related anticancer agents, Expert Opin. Ther. Pat.,
1996, 6(12), 1285-94. Chem.Abstr., 126, 83873f.
ISMAIL M. et al, Spectroscopie studies of 9-hydroxyellipticine binding to DNA, Biopoly-
mers, 1998, 46 (3), 127-43.
SHI L. et al, Mining the National Cancer lnstitute anticancer drug discovery database:
cluster analysis of ellipticine analogs with p53-inverse and central nervous system-
selective patterns of activity, Mol. Pharmac0l., 1998, 53 (2), 241-251.
EFFETS INDÉSIRABLES
ALBERICI G. et al., Ellipticine derivatives interact with muscarinic receptors, Biochem.
Pharmacol., 1985, 34, 1701-4.
PALLARDY M. et al, Polyclonal antibodies to ellipticinium acetate : structure-acti-
vity relationships and comparison with human antiellipticinium lgM, Int. J. Immu-
nopharmacol., 1987, 9 (2), 151-6.
PERSPECTIVES
HONDA T., NAKANISHI T., Brevet européen: EP 173462 (5.3.1986). Chem.Abstr., 107,
134 626.
BISAGNI E., Ellipticines et leurs analogues substitués sur leur position 1: hypothèses de
travail et résultats biologiques, Actual. Chimie Therap., 1990, 17, 33-59.
NGUYEN C.H. et al, Further SAR in the new antitumor 1-amino-substituted gamma car-
bolines and 5H-benzo{e}pyrido{4,3-b}indoles series, Anticancer Drug Design, 1992,
7(3), 235-40.
JASZTOLD-HOWORKO R. et al, Synthesis and evaluation of 9-hydroxy-5-methy!-
(and5,6-dimethyl)-6H-pyrido{4,3-b)carbazole-1N-{(dialkylamino)alkyl)carboxamides,
a new promising series of antitumor olivacine derivatives. J. Med. Chem., 1994, 37
(15), 2445-52.